Merida Therapeutics has launched with a $121 million Series A funding round co-led by Third Rock Ventures and Bain Capital Life Sciences. This funding will support the company's development of Fc-based therapeutics for autoimmune disorders.
Merida Therapeutics has launched with a $121 million Series A funding round co-led by Third Rock Ventures and Bain Capital Life Sciences. This funding will support the company's development of Fc-based therapeutics for autoimmune disorders.
04/08/25, 3:25 PM
Location
cambridgeMoney raised
$121 million
Industry
therapeutics
biotechnology
health care
Round Type
series a
Investors
Perceptive Xontogeny Venture Funds, Gv, Bvf Partners, Bain Capital Life Sciences, Third Rock Ventures
Merida Therapeutics has officially unveiled its drug development platform and secured $121 million in Series A financing. Third Rock Ventures co-led the round alongside Bain Capital Life Sciences and other notable investors. The funds will be used to advance their protein engineering platform aimed at treating autoimmune diseases like Graves' disease. The lead program is focused on precision therapeutics targeting pathogenic antibodies.
Company Info
Location
cambridge, massachusetts, united states
Additional Info
Merida is advancing a precision immunology approach for antibody-driven diseases that selectively and durably eliminate their pathogenic drivers. This approach, enabled by advances in protein engineering and immunology, has the potential to address numerous autoimmune and allergic conditions that are inadequately treated today.